Description
MGAT2 Antibody | 61-381 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Homology: Predicted species reactivity based on immunogen sequence: Mouse, Pig, Rat
Immunogen: This MGAT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 409-439 amino acids from the C-terminal region of human MGAT2.
Research Area: Other
Tested Application: WB, Flow
Application: For WB starting dilution is: 1:1000
For FACS starting dilution is: 1:10~50
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 52 kDa
Validation: N/A
Isoform: N/A
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Clonality: Polyclonal
Clone: N/A
Isotype: Rabbit Ig
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: batch dependent
Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Alternate Name: Alpha-1, 6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase, Beta-1, 2-N-acetylglucosaminyltransferase II, GlcNAc-T II, GNT-II, Mannoside acetylglucosaminyltransferase 2, N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase II, MGAT2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: MGAT2 (UDP-N-acetylglucosamine:alpha-6-D-mannoside-beta-1, 2-N-acetylglucosaminyltransferase II) is a Golgi enzyme catalyzing an essential step in the conversion of oligomannose to complex N-glycans. The enzyme has the typical glycosyltransferase domains: a short N-terminal cytoplasmic domain, a hydrophobic non-cleavable signal-anchor domain, and a C-terminal catalytic domain. Mutations in MGAT2 may lead to carbohydrate-deficient glycoprotein syndrome, type II.